Bank Of New York Mellon Corp Akebia Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

$521 Trillion
Q1 2024

A detailed history of Bank Of New York Mellon Corp transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Bank Of New York Mellon Corp holds 18,762 shares of AKBA stock, worth $21,013. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,762

Previous 71,831 73.88%

Holding current value

$21,013

Previous $89.1 Million 61.45%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	SELL	$1.27 - $2.24 $67,397 - $118,874	-53,069 Reduced 73.88%	18,762 $34.3 Million
Q4 2023 Jan 29, 2024	BUY	$0.8 - $1.28 $0 - $1	1 Added 0.0%	71,831 $89.1 Million
Q3 2023 Oct 24, 2023	SELL	$0.87 - $1.84 $5 - $11	-6 Reduced 0.01%	71,830 $81.9 Million
Q1 2023 May 09, 2023	BUY	$0.56 - $1.15 $40,228 - $82,611	71,836 New	71,836 $40.3 Million
Q4 2022 Feb 14, 2023	BUY	$0.25 - $0.58 $17,959 - $41,664	71,836 New	71,836 $41,000

Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $181,455 - $379,921	-567,047 Reduced 88.76%	71,836 $26,000
Q1 2022 May 11, 2022	BUY	$0.72 - $2.93 $10,107 - $41,131	14,038 Added 2.25%	638,883 $459,000
Q4 2021 Feb 11, 2022	BUY	$2.26 - $3.34 $74,616 - $110,273	33,016 Added 5.58%	624,845 $1.41 Million
Q3 2021 Nov 12, 2021	BUY	$2.35 - $3.88 $69,733 - $115,135	29,674 Added 5.28%	591,829 $1.7 Million
Q2 2021 Aug 11, 2021	SELL	$2.83 - $4.2 $96,429 - $143,110	-34,074 Reduced 5.71%	562,155 $2.13 Million
Q1 2021 May 13, 2021	SELL	$2.92 - $5.06 $180,111 - $312,110	-61,682 Reduced 9.38%	596,229 $2.02 Million
Q4 2020 Feb 09, 2021	BUY	$2.22 - $3.78 $177,344 - $301,965	79,885 Added 13.82%	657,911 $1.84 Million
Q3 2020 Nov 12, 2020	SELL	$2.39 - $13.08 $127,343 - $696,928	-53,282 Reduced 8.44%	578,026 $1.45 Million
Q2 2020 Aug 12, 2020	BUY	$6.67 - $13.58 $268,174 - $545,997	40,206 Added 6.8%	631,308 $8.57 Million
Q1 2020 May 06, 2020	SELL	$4.1 - $10.24 $415,149 - $1.04 Million	-101,256 Reduced 14.62%	591,102 $4.48 Million
Q4 2019 Feb 14, 2020	BUY	$3.16 - $6.73 $75,211 - $160,180	23,801 Added 3.56%	692,358 $4.38 Million
Q3 2019 Nov 07, 2019	SELL	$3.55 - $5.4 $15,325 - $23,311	-4,317 Reduced 0.64%	668,557 $2.62 Million
Q2 2019 Aug 12, 2019	BUY	$4.1 - $8.05 $487,412 - $956,992	118,881 Added 21.46%	672,874 $3.26 Million
Q1 2019 May 14, 2019	BUY	$5.41 - $8.73 $29,203 - $47,124	5,398 Added 0.98%	553,993 $4.54 Million
Q4 2018 Feb 11, 2019	BUY	$5.39 - $9.15 $1.8 Million - $3.05 Million	333,569 Added 155.13%	548,595 $3.03 Million
Q3 2018 Nov 09, 2018	BUY	$7.44 - $10.65 $2,276 - $3,258	306 Added 0.14%	215,026 $0
Q2 2018 Aug 06, 2018	BUY	$9.15 - $11.34 $128,914 - $159,769	14,089 Added 7.02%	214,720 $2.14 Million
Q1 2018 May 15, 2018	SELL	$9.53 - $15.68 $483,761 - $795,948	-50,762 Reduced 20.19%	200,631 $1.91 Million
Q4 2017 Feb 09, 2018	BUY	$14.24 - $19.59 $3.58 Million - $4.92 Million	251,393	251,393 $3.74 Million

Others Institutions Holding AKBA

# of Institutions

127

Shares Held

56.7M

Call Options Held

937K

Put Options Held

743K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $206M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account

Bank Of New York Mellon Corp Akebia Therapeutics, Inc. Transaction History